Retroviral delivery system

A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of t...

Full description

Saved in:
Bibliographic Details
Main Authors DEVA PATIL, SUSAN MARY KINGSMAN, ALAN JOHN KINGSMAN, FIONA MARGARET ELLARD, KYRIACOS ANDREOU MITRAPHANOUS
Format Patent
LanguageEnglish
Published 24.11.1999
Edition6
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by the retroviral delivery system; wherein the first nucleotide sequence is heterologous with respect to at least one of the other nucleotide sequences; and wherein the first nucleotide sequence codes for at least a part of a rabies G protein or a mutant, variant, derivative or fragment thereof that is capable of recognising the target site. The retrovirus may be HIV-1, EIAV or MLV. The retroviral delivery system may be used in the manufacture of medicaments for disorders requiring gene therapy. A method of contacting a target cell with the delivery system, and transduced cells resulting from the method are also claimed.
Bibliography:Application Number: GB19980011153